



Edgar Filing: IMMUNOMEDICS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On January 18, 2017, Immunomedics, Inc. (the “Company”) issued a press release titled “Immunomedics Announces New Data for IMMU-132 at Investor R&D Day.” The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

Also on January 18, 2017, at the Company’s Investor R&D Day being held at The Roosevelt Hotel in New York, New York, the Company delivered a presentation entitled “Advanced Antibody-Based Therapeutics.” On the same date and at the same investor event, the company Health Advances delivered a presentation entitled “R&D Day Presentation: Commercial Assessment and Competitive Landscape.” The full texts of both presentations are attached to this current report on Form 8-K as Exhibits 99.2 and 99.3, respectively, and are incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
99.1	Press Release of Immunomedics, Inc., dated January 18, 2017, titled “Immunomedics Announces New Data for IMMU-132 at Investor R&D Day.”
99.2	Advanced Antibody-Based Therapeutics (a presentation by Immunomedics, Inc.)
99.3	R&D Day Presentation: Commercial Assessment and Competitive Landscape (a presentation by Health Advances)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IMMUNOMEDICS, INC.**

By: /s/ Michael R. Garone

Name: Michael R. Garone

Title: Vice President, Finance and Chief Financial Officer

Date: January 18, 2017

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
99.1	Press Release of Immunomedics, Inc., dated January 18, 2017, titled “Immunomedics Announces New Data for IMMU-132 at Investor R&D Day.”
99.2	Advanced Antibody-Based Therapeutics (a presentation by Immunomedics, Inc.)
99.3	R&D Day Presentation: Commercial Assessment and Competitive Landscape (a presentation by Health Advances)